Fire-Side Chat: Discussing the Journey of Gaining Approval for GA Drugs & Current Challenges In the Market
Time: 1:00 pm
day: Conference Day Two
Details:
- Discussing the path to gain approval for complement inhibitors for GA by the FDA and the rejections from the EMA
- Minimizing toxic side effects and reducing retinal inflammation when delivering via intravitreal injections
- Debating the optimal less invasive, longer lasting administration route to reduce frequence of injections for elderly patient population
- Understanding how the GA drug can be improved to stop disease progression and be used to treat intermediate AMD before disease reaches atrophic stage
